Loading...
Acacia Pharma raises £15 million to advance clinical development of lead products for supportive care
09-Sep-2013
- United Kingdom
Advertisement
Acacia Pharma announced it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond Ventures also participated in the round. Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo A/S have joined the Board of Acacia Pharma as Non-executive Directors.
Acacia Pharma will use the proceeds to:
- complete Phase III development of APD421 for the prevention of post-operative nausea & vomiting (PONV);
- complete Phase II development of APD403 for the prevention of chemotherapy induced nausea & vomiting (CINV); and
- develop the commercial presentation of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
© 1997-2026 LUMITOS AG, All rights reserved